Adma Biologics Inc risk profile
39 Normal where most of the sector sits
Measured 21 October 2026 from ADMA's filed statements. Recomputed nightly.
39 (Normal), driven by Concentration at 99, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 70 | Stretched | Volatile | One-year price volatility — 54.3% |
| Operating pressure | 7 | Contained | Worsening | Costs outgrowing revenue — -8.7 percentage points |
| Cash conversion | 55 | Elevated | Worsening | Cash conversion — 0.34x |
| Leverage and coverage | 0 | Contained | Easing | Net debt to EBITDA — -0.08x |
| Competitive position | 20 | Normal | Stable | R&D-intensity gap against peers — -16.9 percentage points |
| Concentration | 99 | Acute | Stable | Geographic concentration — 9,762 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Adma Biologics Inc